Results 241 to 250 of about 61,189 (311)

Advances in Wine Yeast Autolysis: Biochemical and Molecular Mechanisms, and the Release of Organic Compounds in White and Sparkling Wines—An Updated Review

open access: yesComprehensive Reviews in Food Science and Food Safety, Volume 25, Issue 3, May 2026.
ABSTRACT Wine yeasts play a central role in alcoholic fermentation and significantly contribute to the sensory attributes of wines through cellular autolysis during lees aging (sur lie), especially in white wines. This process releases organic compounds that alter the wine's chemical and sensory profile.
José Ricardo Machado dos Santos   +1 more
wiley   +1 more source

Draft genome of Neofabraea vagabunda, the agent of bull's eye rot

open access: yesAnnals of Applied Biology, Volume 188, Issue 3, Page 941-946, May 2026.
Circular representation of the 12 major scaffolds from the draft genome of Neofabraea vagabunda showing gene density, density of repeated regions, GC content, and functional features (secrete and membrane proteins, proteases, and CAZymes) distribution.
Saveria Mosca   +4 more
wiley   +1 more source

Hypoglycemia Occurrence and Risk Factors in Insulin Independent Patients After Total Pancreatectomy With Islet Autotransplantation

open access: yesClinical Transplantation, Volume 40, Issue 5, May 2026.
ABSTRACT Background Total pancreatectomy with islet auto‐transplantation (TPIAT) alleviates pain and preserves islet function in patients with severe pancreatitis. Although approximately one third of recipients achieve insulin independence, spontaneous hypoglycemia has been observed in this population. Its frequency, risk factors, and management remain
Azza Hassaan   +10 more
wiley   +1 more source

The Placebo Effect in Rare Disease Clinical Trials: Measurement, Impact, and Statistical Approaches for Patient‐as‐Own‐Control Designs

open access: yesClinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT A frequently cited concern regarding patient‐as‐own‐control trial designs in rare disease is the potential for placebo and related effects to inflate apparent treatment efficacy. Whether this concern is disqualifying or manageable has not been systematically evaluated.
Marshall L. Summar, Janet Woodcock
wiley   +1 more source

A thermostable and highly active fungal GH3 β-glucosidase generated by random and saturation mutagenesis. [PDF]

open access: yesProc Jpn Acad Ser B Phys Biol Sci
Matsuzaki C   +8 more
europepmc   +1 more source

Acarbose or Canagliflozin vs. Placebo to Ameliorate Post‐Bariatric Hypoglycaemia: The Clinical Outcomes of the HypoBar I Randomised Clinical Trial

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4205-4215, May 2026.
ABSTRACT Aims Treatment options for post‐bariatric hypoglycaemia (PBH) are empirical. We aimed to investigate the efficacy and safety of acarbose and canagliflozin for the treatment of PBH. Materials and Methods We performed a randomised, double‐blinded, cross‐over, placebo‐controlled clinical trial where placebo, acarbose 50 mg thrice daily, and ...
Carolina B. Lobato   +9 more
wiley   +1 more source

Development of a β-glucosidase improved for glucose retroinhibition for cellulosic ethanol production: an integrated bioinformatics and genetic engineering approach. [PDF]

open access: yesBiotechnol Biofuels Bioprod
Azevedo RDS   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy